Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease

Inclusion Criteria: * Patients with a documented history of Parkinson's disease according to UPDRS,fluctuator and non-fluctuator patients, Hoehn and Yahr score \<5; * stabilized on optimal antiparkinsonian treatments unmodified for 4 weeks prior to study entry; * presenting an Excessive Daytime Sleepiness as indicated by an ESS\>or=12 Exclusion Criteria: * Patients with a known diagnosis of other degenerative parkinsonian syndromes (e.g. Progressive supra-nuclear palsy, multisystemic atrophy, corticobasal degenerescence, diffuse Lewy's Body dementia) * Patients who have shift work, chronic or occasional sleep deprivation, circadian rhythm disorders * Patients with a severe depression indicated by (BDI\>= 16)or at suicidal risk (BDI item G\>0) or depression treated for less than 8 weeks * Patients with a cognitive impairment